Vaxart, Inc.

121 articles with Vaxart, Inc.

• 

  Evidence Building for a Mix and Match Approach to COVID-19 Vaccines

  7/12/2021

  Morgan had determined that adding one dose of the Moderna or Pfizer-BioNTech mRNA vaccine to one of Oxford-AstraZeneca’s viral vector technology would equal stronger immunity. 
• 

  Clinical Catch-Up: September 14-18

  9/21/2020

  It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.

• Vaxart Announces FDA Clearance of IND Application for Oral COVID-19 Vaccine and Provides Update on COVID-19 Program

  9/14/2020

  Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Company’s Investigational New Drug (IND) application for its Phase 1 clinical trial evaluating its oral COVID-19 vaccine candidate

• 

  Biopharma Update on the Novel Coronavirus: September 14

  9/14/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.

• Vaxart’s Oral COVID-19 Vaccine Candidate Induces Potent Systemic and Mucosal Immune Responses in Preclinical Studies

  9/8/2020

  Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced pre-publication of a manuscript titled “Preclinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection.”

• Vaxart, Inc. to Participate in September Virtual Investor Conferences

  9/3/2020

  - H.C. Wainwright: 22 nd Annual Global Investment Conference - September 14 th – 16 th - Sachs Associates: 20 th Annual Biotech in Europe Forum - September 21 st  – 24 th - SVB Leerink: CybeRx Series: Vaccine Forum - September 23 rd & – 24 th

• Vaxart Appoints Karen J. Wilson to its Board of Directors

  8/27/2020

  Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced the appointment of Karen J. Wilson to its Board of Directors and as chair of its Audit Committee.

• Vaxart Announces IND Filed for COVID-19 Vaccine

  8/10/2020

  Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its COVID-19 Investigational New Drug (IND) application has been filed with the US Food and Drug Administration (FDA).

• Vaxart Announces Second Quarter 2020 Results

  8/6/2020

  Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, provided an update on its financials for the second quarter of 2020, and a corporate update.

• Norovirus Gastroenteritis Costs an Estimated $10.6 Billion Each Year in the United States Over 90% of norovirus' total annual cost is due to sporadic spread in the community.

  7/16/2020

  Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, and has a Phase 2 ready norovirus vaccine program, today announced that a new study was published in the Journal of Infectious Diseases today, which concluded that norovirus gastroenteritis costs the United States an estimated median of $10.6 billion each year. In part

• Vaxart Raises Approximately $90M in Gross Proceeds Through its At-The-Market-Facility

  7/13/2020

  Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced that it has raised gross proceeds of approximately $90 million through its At-the-Market facility with participation based on interest received from RA Capital Management and Invus.

• Vaxart’s COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp SpeedOWS to Test First Oral COVID-19 Vaccine in Non-Human Primates

  6/26/2020

  Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced that its oral COVID-19 vaccine has been selected to participate in a non-human primate (NHP) challenge study, organized and funded by Operation Warp Speed,

• 

  Vaxart's COVID-19 Vaccine Candidate Tapped for Operation Warp Speed Primate Study

  6/26/2020

  One month after Vaxart announced the selection of its lead vaccine candidate for COVID-19, the Bay Area-based company said it has been selected to participate in the U.S. government’s Operation Warp Speed program.
• 

  Biopharma Update on the Novel Coronavirus: June 26

  6/26/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 26, 2020.

• Babson Diagnostics Receives FDA Emergency Use Authorization for its SARS-CoV-2 IgG Antibody Test

  6/25/2020

  Babson Diagnostics (Babson), a transformative diagnostic blood testing company, announced today that its SARS-CoV-2 IgG antibody test, Babson Diagnostics aC19G1, has received emergency use authorization (EUA) from the Food and Drug Administration (FDA). Babson Diagnostics aC19G1 is a COVID-19 serology test that enables the qualitative detection of IgG antibodies to SARS-CoV-2 with 100% sensitivity and 100% specificity. T

• Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP

  6/25/2020

  Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year Through Large Scale Lyophilization, Tableting and Coating

• Vaxart, Inc. Set to Join Russell 3000® Index

  6/24/2020

  Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it has joined the broad-market Russell 3000 Ò Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective Monday, June 29 th 2020 after the U.S. market opening. Annual Russell indexes reconstitution captures t

• Vaxart, Inc. to Present at the H.C. Wainwright Virtual Fireside Chat SeriesLive Webcast on Thursday June 25th at 10:25 am ET

  6/23/2020

  Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that Andrei Floroiu, Chief Executive Officer, will participate in the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25, at 10:25 am ET H.C. Wainwright Virtual Fireside Chat Series    Date: Thursday, June 25 t

• Vaxart, Inc. Appoints New CEO to Accelerate Advancement of COVID-19 and Other Programs

  6/15/2020

  Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced that effective today it has appointed Andrei Floroiu as Chief Executive Officer.

• 

  Biopharma Update on the Novel Coronavirus: June 15

  6/15/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 15, 2020.